Phibro Animal Health Announces CEO Transition: Jack Bendheim to Executive Chairman, Dani Bendheim to CEO

PHIBRO ANIMAL HEALTH CORP

Jack C. Bendheim will resign as CEO and President effective July 1, 2026, and assume the new role of Executive Chairman.
Daniel (Dani) Bendheim, age 53, current EVP Corporate Strategy, will become CEO and President on July 1, 2026.
Dani Bendheim has been with Phibro since 1997 and served as VP Business Development, President Performance Products, and EVP Corporate Strategy.
Jack Bendheim, son of founder, will continue as Chairman of the Board; the Board unanimously supports the transition.
A press release announcing the leadership change was issued on December 18, 2025, and furnished as Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.